| Name | Title | Contact Details |
|---|
Spectranetics is dedicated to managing every lead and eradicating restenosis and amputation. We do this by helping physicians, patients, and hospitals maximize cardiovascular health. Our company is committed to inventing, selling, and supporting technology that enables success during the most challenging minimally invasive cardiovascular procedures. We provide expert physician training, including the only lead removal simulator in the industry, as well as extensive patient and physician education. The Company’s Lead Management (LM) division is dedicated to helping physicians safely manage every lead. We provide the expert tools, training and ongoing support – including the only available lead extraction simulator – that allow physicians precision, control and versatility while extracting leads, so they can focus more on the patient’s overall status while generating positive outcomes. The Vascular Intervention (VI) division is dedicated to helping physicians address the challenges of peripheral and coronary artery disease. We provide expert tools, training, ongoing support, and patient education so that you can help eradicate restenosis and amputation
Ga Assoc For Primary Health Care is a Decatur, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
American Society of Pain Educators is a Montclair, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
WellDyne is a Englewood, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MolecularMD founders Brian Druker (lead clinical investigator for Gleevec, the first molecularly-targeted anticancer agent) and Sheridan G. Snyder (entrepreneur, founder of Genzyme and Upstate Biotechnology) came together with the mission of providing precise, standardized molecular testing for new oncology drugs. The company’s initial accomplishment was in developing and implementing the only standardized assay for quantification of BCR-ABL expression levels, which proved critical to pharmaceutical sponsors in satisfying regulators for approval of the second-generation ABL kinase inhibitors nilotinib (Tasigna, Novartis) and dasatinib (Sprycel, BMS). With that foundational success in supporting pivotal international studies with centralized, high-quality diagnostic services, MolecularMD has become a preferred provider of molecular diagnostics products and services to pharmaceutical and biotech drug developers. Capabilities range from specialty molecular testing services performed in MolecularMD’s centralized CLIA-certified and CAP-accredited laboratory, to development of FDA approved companion diagnostics to support new drug registrations.